Oxytocin has extensive human research and approved medical uses, but its effects depend heavily on the indication, route, dose and population. That evidence does not support a simple general claim that oxytocin reliably improves bonding, mood, trust or libido.
Still uncertain: A simple reliable bonding, trust, mood or libido-enhancement effect across populations.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
Nonapeptide hormone
Entity type
Peptide hormone / hormone analogue
Research focus
Obstetrics; intranasal social/behavioural research
Human evidence
Oxytocin has a large heterogeneous human literature. Effects on social/psychiatric outcomes vary by context, and a randomized crossover trial in women with sexual dysfunction found no significant treatment effect beyond placebo.
Regulatory status
Licensed oxytocin medicines exist for specific obstetric indications; nasal behavioural/wellness uses are not equivalent approved indications.
Main limitations
A simple reliable bonding, trust, mood or libido-enhancement effect across populations.
Safety
Risks depend strongly on route and clinical context. Obstetric use can have serious maternal/fetal risks; intranasal long-term safety in vulnerable groups is less certain.
Evidence reviewed
2026-09-18
i
Oxytocin has a large heterogeneous human literature. Effects on social/psychiatric outcomes vary by context, and a randomized crossover trial in women with sexual dysfunction found no significant treatment effect beyond placebo.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Risks depend strongly on route and clinical context. Obstetric use can have serious maternal/fetal risks; intranasal long-term safety in vulnerable groups is less certain.
Clinical risks depend strongly on route and indication. Systemic obstetric oxytocin can cause uterine hyperstimulation, water intoxication/hyponatraemia and cardiovascular effects; intranasal research does not establish a general safe cognitive or bonding enhancer.
Technical details
Mechanism / biologyActivates oxytocin receptors; established uterotonic/lactation physiology and experimental CNS/social effects.
Route / formulation boundarySeparate injectable obstetric evidence from intranasal research evidence.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceVerified study/label regimen evidence is available. UK licensed hospital dosing example. Open descriptive regimen evidence →
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
2structured study records
3outcome records
8linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
